DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161477

Antiretroviral therapy outcome in human immuno-deficiency virus infected patients in a tertiary care hospital

Hasitha Diana Manohar, Smita Shenoy, Muralidhar Varma, Asha Kamath, Chaithanya Malalur, Kurady Laxminarayana Bairy, Amod Tilak, Kavitha Saravu

Abstract


Background: Human immunodeficiency virus (HIV) presently accounts for the highest number of deaths due to any infective agent in the world. The present study assessed the one year treatment outcome following antiretroviral therapy in HIV positive, treatment naïve patients in a tertiary care hospital.

Methods: Adult HIV positive, antiretroviral treatment naive patients who were started on antiretroviral therapy (ART) between 1st January 2011 and 31st May 2013 were included in the study. Data was collected from their case records. CD4+cell count, haemoglobin level, weight, occurrence of opportunistic infections (OIs) and adverse drug reactions (ADRs) were analysed at baseline, 6 and 12 months following start of antiretroviral therapy. Data was analysed using parametric and nonparametric tests.

Results: Data of 325 patients was analysed. Overall, the median increase in CD4+ count at 1 year after initiation of treatment was observed to be clinically significant. Patients on tenofovir based regimen showed a significantly greater increase in the median CD4+ count (P = 1.12×10-05) and haemoglobin (P = 0.002) as compared to those on non-tenofovir based regimen. A total of 151 ADRs were recorded in the study, of which the most common were skin rash 24%, anaemia and gastrointestinal side effects 17% each. Frequency of opportunistic infections gradually declined after ART. At the end of 1 year of treatment, the cumulative loss to follow up was 7.4%.

Conclusions: By following the current national guidelines, the desired immunological and clinical response following initiation of ART can be achieved while minimizing drug toxicity.


Keywords


Antiretroviral therapy, Clinical outcome, Tenofovir, Nontenofovir

Full Text:

PDF

References


National Aids Control Organisation. ART guidelines for HIV-Infected Adults and Adolescents including Post-exposure prophylaxis. New Delhi: NACO; 2013. Available at, http://www.naco.gov.in/upload/Policies% 20&%20Guidelines/Antiretroviral%20Therapy%20Guidelines%20for%20HIV Infected%20Adults%20and%20Adolescents.pdf. Accessed on 25 August, 2014.

Safrin S. Antiviral agents. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th edition. New Delhi: Tata McGraw Hill companies; 2009:856.

Bachani D, Garg R, Rewari BB, Hegg L, Rajasekaran S, Deshpande A, et al. Two-year treatment outcomes of patients enrolled in India’s national first-line antiretroviral therapy programme. Natl Med J India. 2010;23:7-12.

Shah B, Walshe L, Saple DG, Mehta SH, Ramnani JP, Kharkar R, et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis. 2007;44(9):1235-44.

Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AS, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS patient care STDs. 2005;19(8):526-37.

Cornett JK, Kirn TJ. Laboratory diagnosis of HIV in adults: a review of current methods. Clin Infect Dis 2013;57:712.

Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281.

Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the Global AIDS Epidemic, 2013. Geneva: UNAIDS; 2013. Available at, http://www.unaids.org/en/resources/documents/2013/name, 85053.pdf. Accessed on 25 August 2014.

ART-LINC of IeDEA Study Group, Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23:1867.

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387.

Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487.

Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH. Clinical outcomes and CD4-cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888-99.

Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401-10.

Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-95.

Hira SK, Dupont HL, Lanjewar DN, Dholakia YN. Severe weight loss: the predominant clinical presentation of tuberculosis in patients with HIV infection in India. Natl Med J India. 1998;11:256-8.

Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107-10.

Smith CJ, Sabin CA, Lampe FC, Kinloch-de-Loes S, Gumley H, Carroll A, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS. 2003;17:963-9.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-78.

d'Arminio MA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499-507.

Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.

Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-24.

Anabwani G, Navario P. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview. Nutrition 2005;21:96-9.

Mayo J, Collazos J, Martinez E, Ibarra S. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med. 2002;162:1095-8.

DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med. 2000;133:447-54.

Praska JL, Kripalani S, Seright AL, Jacobsen TA. Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. Ann Pharmacother. 2005;39:1441-5.

Vanhove GF, Schapiro JM, Winters MA. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955-6.

Deeks S, Beatty G, Cohen PT. Viral load and CD4+ T-cell changes in patients failing potent protease inhibitor therapy. Abstract 419. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; Chicago, United States; 1998.

Montaner JS, Reiss P, Cooper D. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, the Netherlands, Canada, and Australia Study. JAMA. 1998;279:930-7.

Melbourne KM., Geletko SM, Brown SL, Willey-Lessne C, Chase S, Fisher A. Medication Adherence in Patients with HIV Infection: a comparison of two measurement methods. AIDS. 1999;9(5):329-38.

Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, et al. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr. 2007;44(4):451-5.

Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003;17(15):2267–9.

Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr. 2004;37(5):1566-9.

Pujari S, Dravid A, Gupte N, Joshix K, Bele V. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. J Int AIDS Soc. 2008;10(8):196.

Palella FJ, Deloria-Knoll M, Chmiel JS. Survival benefit of initiating antiretroviral therapy in HIV infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138(8):620-6.